A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma
2015 ◽
Vol 64
(10)
◽
pp. 1251-1260
◽
2018 ◽